NCT04184271

Brief Summary

The study aim is to characterize the kinetics of silver and fluoride after topical application of silver diamine fluoride.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
16

participants targeted

Target at below P25 for phase_2

Timeline
Completed

Started Aug 2017

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2017

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 30, 2017

Completed
1.5 years until next milestone

Study Completion

Last participant's last visit for all outcomes

March 31, 2019

Completed
8 months until next milestone

First Submitted

Initial submission to the registry

November 28, 2019

Completed
5 days until next milestone

First Posted

Study publicly available on registry

December 3, 2019

Completed
9 months until next milestone

Results Posted

Study results publicly available

August 14, 2020

Completed
Last Updated

January 26, 2021

Status Verified

July 1, 2020

Enrollment Period

2 months

First QC Date

November 28, 2019

Results QC Date

July 7, 2020

Last Update Submit

January 11, 2021

Conditions

Keywords

adultfluoridesilversilver diamine fluoridepharmacokinetics

Outcome Measures

Primary Outcomes (6)

  • Observed Fluoride Urinary Recovery

    24 hour fluoride urinary recovery (in mg)

    baseline to 24 hours

  • Observed Silver Tmax

    Observed silver time to maximum serum concentration in hours

    baseline, 30 minutes, and 1, 2, 3, 4, 6, 8, 12, and 24 hours

  • Observed Silver Cmax

    Observed silver maximum serum concentration in ng/mL

    baseline, 30 minutes, and 1, 2, 3, 4, 6, 8, 12, and 24 hours

  • Observed Silver Baseline-Corrected Cmax

    Observed silver baseline-corrected maximum serum concentration in ng/mL

    baseline, 30 minutes, and 1, 2, 3, 4, 6, 8, 12, and 24 hours

  • Observed Silver t1/2

    Observed silver serum elimination half-life in hours

    baseline, 30 minutes, and 1, 2, 3, 4, 6, 8, 12, and 24 hours

  • Observed Silver 24 Hour Urinary Concentration

    Observed silver 24-hour urinary concentration in ng/mL

    baseline to 24 hours

Study Arms (1)

38% silver diamine fluoride

EXPERIMENTAL

38% silver diamine fluoride, topical, 1 drop, single application

Drug: 38% silver diamine fluoride

Interventions

Topical application of SDF to teeth

Also known as: Advantage Arrest
38% silver diamine fluoride

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • years or older, minimum 20 teeth, healthy, not taking prescription or OTC medications

You may not qualify if:

  • pregnant, weighed less than 50 kg, had oral mucositis or ulcerative lesions, known sensitivity to silver or fluoride

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Washington Institute of Translational Health Sciences

Seattle, Washington, 98195, United States

Location

Related Publications (1)

  • Lin YS, Rothen ML, Milgrom P. Pharmacokinetics of 38% topical silver diamine fluoride in healthy adult volunteers. J Am Dent Assoc. 2019 Mar;150(3):186-192. doi: 10.1016/j.adaj.2018.10.018.

MeSH Terms

Conditions

Dental Caries

Interventions

silver diamine fluoride

Condition Hierarchy (Ancestors)

Tooth DemineralizationTooth DiseasesStomatognathic Diseases

Results Point of Contact

Title
Peter Milgrom
Organization
Advantage Silver Dental Arrest, LLC

Study Officials

  • Peter Milgrom, DDS

    University of Washington

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
phase 2
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Model Details: Open label exposure--response study
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 28, 2019

First Posted

December 3, 2019

Study Start

August 1, 2017

Primary Completion

September 30, 2017

Study Completion

March 31, 2019

Last Updated

January 26, 2021

Results First Posted

August 14, 2020

Record last verified: 2020-07

Data Sharing

IPD Sharing
Will not share

Locations